MediWound Ltd. (NASDAQ:MDWD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $5.75 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 10.58% from the company’s previous close.

According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “

Other equities research analysts also recently issued reports about the company. SunTrust Banks, Inc. restated a “buy” rating on shares of MediWound in a research note on Monday, June 26th. Jefferies Group LLC set a $10.00 price target on shares of MediWound and gave the company a “buy” rating in a research report on Friday, August 25th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $10.00 price objective on shares of MediWound in a research note on Monday, September 18th. Cowen and Company started coverage on shares of MediWound in a research note on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price objective on the stock. Finally, ValuEngine downgraded shares of MediWound from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.15.

Shares of MediWound (MDWD) opened at 5.20 on Wednesday. MediWound has a 52 week low of $4.25 and a 52 week high of $8.25. The company’s market capitalization is $114.16 million. The company has a 50-day moving average price of $5.83 and a 200-day moving average price of $6.46.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The firm had revenue of $0.69 million for the quarter, compared to analysts’ expectations of $0.69 million. During the same quarter last year, the company posted ($0.34) EPS. The firm’s revenue was up 93.8% compared to the same quarter last year. Analysts predict that MediWound will post ($0.76) earnings per share for the current year.

WARNING: “MediWound Ltd. (MDWD) Upgraded to “Buy” at Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/mediwound-ltd-mdwd-upgraded-to-buy-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its holdings in MediWound by 19.7% during the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 8,745 shares during the period. Wellington Management Group LLP increased its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares in the last quarter. Renaissance Technologies LLC increased its position in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 1,300 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after buying an additional 342,165 shares in the last quarter. Institutional investors own 19.55% of the company’s stock.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.